Heinze, Britta
Schirbel, Andreas
Nannen, Lukas
Michelmann, David
Hartrampf, Philipp E.
Bluemel, Christina
Schneider, Magdalena
Herrmann, Ken
Haenscheid, Heribert
Fassnacht, Martin
Buck, Andreas K.
Hahner, Stefanie
Funding for this research was provided by:
Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg (F-365)
Deutsche Forschungsgemeinschaft (AL 203/1-1, CRC/Transregio 205/1)
Else Kröner-Fresenius-Stiftung (2010_EKES.29)
Universitätsklinikum Würzburg
Article History
Received: 17 December 2020
Accepted: 20 June 2021
First Online: 3 July 2021
Declarations
:
: Collection of patient samples for autoradiographic binding experiments was approved by the ethical committee of the University of Wuerzburg, No. 88/11. Animal experiments were approved and performed in compliance with the guidelines of the local animal care authorities (Az. 55.2–2531.01–93/10). Human scintigraphic imaging with [<sup>123</sup>I]IMTO <b>1</b> was routine diagnostics based on our manufacturing license. The newly developed radiopharmaceutical [<sup>123/131</sup>I]IMAZA <b>4</b> was used according to §13.2b of the German Pharmaceuticals Act. [<sup>131</sup>I]IMAZA <b>4</b> was administered in a patient with a life-threatening disease and tumor progress following standard treatment after individual ethical counseling by the ethical board of the University Hospital of Wuerzburg, Germany. Written informed consent was obtained prior to diagnostic evaluation and therapy.
: Not applicable.
: Not applicable.
: AS and SH filed a patent application WO/2014/048568 for IMAZA. All other authors declare no potential conflicts of interest.